NASDAQ:CHRSCoherus Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.82 +0.08 (+0.43 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$18.76Now: $18.82▼$19.6350-Day Range$14.49MA: $17.00▼$19.1652-Week Range$10.86Now: $18.82▼$23.91Volume1.08 million shsAverage Volume2.24 million shsMarket Capitalization$1.33 billionP/E Ratio9.60Dividend YieldN/ABeta2.05 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCoherus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.00, Coherus Biosciences has a potential upside of 70.0% from its current price of $18.82.Amount of Analyst CoverageCoherus Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesCoherus Biosciences has received 390 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCoherus Biosciences has received 373 “underperform” votes. (Add your “underperform” vote.)Community SentimentCoherus Biosciences has received 51.11% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote “Outperform” if you believe CHRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCoherus Biosciences does not currently pay a dividend.Dividend GrowthCoherus Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $187,969.00 in company stock.Percentage Held by InsidersOnly 15.86% of the stock of Coherus Biosciences is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Coherus Biosciences are expected to decrease by -31.97% in the coming year, from $1.47 to $1.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Biosciences is 9.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 15.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Biosciences is 9.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 18.10.Price to Book Value per Share RatioCoherus Biosciences has a P/B Ratio of 12.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.47 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS Previous Symbol CUSIPN/A CIK1512762 Webwww.coherus.com Phone650-649-3530Debt Debt-to-Equity Ratio1.21 Current Ratio3.32 Quick Ratio3.18Price-To-Earnings Trailing P/E Ratio9.60 Forward P/E Ratio12.80 P/E GrowthN/A Sales & Book Value Annual Sales$356.07 million Price / Sales3.75 Cash Flow$1.33 per share Price / Cash Flow14.12 Book Value$1.50 per share Price / Book12.55Profitability EPS (Most Recent Fiscal Year)$1.23 Net Income$89.83 million Net Margins33.42% Return on Equity190.82% Return on Assets41.58%Miscellaneous Employees232 Outstanding Shares70,910,000Market Cap$1.33 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:CHRS Rates by TradingView Receive CHRS News and Ratings via Email Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions How has Coherus Biosciences' stock been impacted by COVID-19 (Coronavirus)? Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CHRS shares have increased by 18.6% and is now trading at $18.82. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Coherus Biosciences? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences. When is Coherus Biosciences' next earnings date? Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Coherus Biosciences. How were Coherus Biosciences' earnings last quarter? Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.44 by $0.10. The biotechnology company had revenue of $116.18 million for the quarter, compared to the consensus estimate of $116.25 million. Coherus Biosciences had a net margin of 33.42% and a return on equity of 190.82%. View Coherus Biosciences' earnings history. What guidance has Coherus Biosciences issued on next quarter's earnings? Coherus Biosciences issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115-117.5 million, compared to the consensus revenue estimate of $118.85 million. What price target have analysts set for CHRS? 8 equities research analysts have issued twelve-month target prices for Coherus Biosciences' shares. Their forecasts range from $26.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $32.00 in the next year. This suggests a possible upside of 70.0% from the stock's current price. View analysts' price targets for Coherus Biosciences. Has Coherus Biosciences been receiving favorable news coverage? News coverage about CHRS stock has trended negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the next few days. View the latest news aboutCoherus Biosciences. Are investors shorting Coherus Biosciences? Coherus Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 13,510,000 shares, an increase of 26.7% from the April 30th total of 10,660,000 shares. Based on an average daily volume of 1,510,000 shares, the short-interest ratio is presently 8.9 days. Approximately 20.9% of the shares of the company are sold short. View Coherus Biosciences' Current Options Chain. Who are some of Coherus Biosciences' key competitors? Some companies that are related to Coherus Biosciences include Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), bluebird bio (BLUE), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE) and Bill.com (RVMD). View all competitors. What other stocks do shareholders of Coherus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Exelixis (EXEL), Intelsat (I), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Pfizer (PFE). Who are Coherus Biosciences' key executives? Coherus Biosciences' management team includes the following people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 64)Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 53)Dr. Peter K. Watler, Chief Technical Officer (Age 57)Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 67)Mr. Vincent R. Anicetti, Chief Operating Officer (Age 64) What is Coherus Biosciences' stock symbol? Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus Biosciences' major shareholders? Coherus Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.69%), JPMorgan Chase & Co. (5.82%), State Street Corp (4.94%), Alliancebernstein L.P. (4.55%), Kohlberg Kravis Roberts & Co. L.P. (4.28%) and Wellington Management Group LLP (3.26%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences. Which institutional investors are selling Coherus Biosciences stock? CHRS stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Two Sigma Investments LP, Rice Hall James & Associates LLC, Rice Hall James & Associates LLC, Ghost Tree Capital LLC, Morgan Stanley, and BlackRock Inc.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences. Which institutional investors are buying Coherus Biosciences stock? CHRS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., JPMorgan Chase & Co., Invesco Ltd., NWQ Investment Management Company LLC, Schroder Investment Management Group, Tang Capital Management LLC, Acadian Asset Management LLC, and FDx Advisors Inc.. View insider buying and selling activity for Coherus Biosciences. How do I buy shares of Coherus Biosciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Coherus Biosciences' stock price today? One share of CHRS stock can currently be purchased for approximately $18.82. How big of a company is Coherus Biosciences? Coherus Biosciences has a market capitalization of $1.33 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe. What is Coherus Biosciences' official website? The official website for Coherus Biosciences is www.coherus.com. How can I contact Coherus Biosciences? Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
